국가: 인도네시아
언어: 인도네시아어
출처: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
MOMETASONE FUROATE MONOHYDRATE
ORGANON PHARMA INDONESIA TBK - Indonesia
MOMETASONE FUROATE MONOHYDRATE
0.051 MG
SEMPROT HIDUNG
DUS,1 BOTOL PLASTIK @ 60 DOSIS
SCHERING-PLOUGH LABO NV - Belgium
2021-07-17
NASONEX Aqueous Nasal Spray Mometasone Furoate COMPOSITION NASONEX Aqueous Nasal Spray is a metered-dose, manual pump spray unit containing a suspension of mometasone furoate. Each metered-dose pump actuation of NASONEX Aqueous Nasal Spray delivers approximately 100 mg of mometasone furoate suspension, containing mometasone furoate monohydrate equivalent to 50 micrograms mometasone furoate. ACTIONS Mometasone furoate is a topical glucocorticosteroid with local anti-inflammatory properties at doses that are not systemically active. It is likely that much of the mechanism for the anti-allergic and anti-inflammatory effects of mometasone furoate lies in its ability to inhibit the release of mediators of allergic reactions. Mometasone furoate significantly inhibits the release of leukotrienes from leucocytes of allergic patients. In cell culture, mometasone furoate demonstrated potency in inhibition of synthesis and release of IL-I, IL-5, IL-6 and TNF α . It is also a potent inhibitor of leukotriene production. In addition, it is an inhibitor of the production of the Th 2 cytokines IL-4 and IL-5, from human CD 4 + T-cells. In studies utilizing nasal antigen challenge, NASONEX Aqueous Nasal Spray has shown anti-inflammatory activity in both the early and late-phase allergic responses. This has been demonstrated by decreases (vs placebo) in histamine and eosinophil activity and reductions (vs baseline) in eosinophils, neutrophils and ephithelial cell adhesion proteins. In patients with seasonal allergic rhinitis, NASONEX Aqueous Nasal Spray demonstrated a clinically significant onset of action within 12 hours after the first dose. Pharmacokinetic Properties Mometasone furoate, administered as an aqueous nasal spray, has a systemic bioavailability of <1% in plasma, using sensitive assay with a lower quantitation limit (LLOQ) of 0.25 pg/ml. Mometasone furoate suspension is very poorly absorbed from the DISETUJUI OLEH BPOM : 09/06/2021 EREG100373VR12100074 - 75 gastrointestinal tract, and the small am 전체 문서 읽기